Key TakeawaysFDA approvals in Q2 2025 expanded treatment options for rare diseases, including the first therapies for immunoglobulin G4-related disease and alkaptonuria.New therapies like atrasentan and beremagene geperpavec introduced innovative solutions in nephrology and dermatology, addressing critical unmet needs.Approvals in respiratory and infectious diseases, such as mepolizumab for eosinophilic COPD, reflect a trend toward targeted […]
